FUJIFILM Diosynth Biotechnologies vs Pfizer CentreOne: CDMO Comparison
How does FUJIFILM Diosynth Biotechnologies compare to Pfizer CentreOne?
As of Aug 2026, FUJIFILM Diosynth Biotechnologies: no FDA inspections on file, 35 EMA/MHRA GMP certificates. Signal Score 86.7. Pfizer CentreOne: 4 FDA inspections (including 3 NAI, 1 VAI and 0 OAI), 14 EMA/MHRA GMP certificates. Signal Score 90.1. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.
Side-by-side comparison of FUJIFILM Diosynth Biotechnologies and Pfizer CentreOne on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Pfizer CentreOne has more FDA inspections on record (4 vs 0) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- FUJIFILM Diosynth Biotechnologies has materially broader EMA GMP coverage (29 active certificates vs 14) — stronger EU footprint.
- FUJIFILM Diosynth Biotechnologies maintains 6 MHRA / UK GMP certificates; Pfizer CentreOne does not.
- Pfizer CentreOne appears as a manufacturing partner on more matched clinical programs (369 vs 0) — a broader sponsor book.
Across the cross-modality scorecard, Pfizer CentreOne carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.
Frequently asked: FUJIFILM Diosynth Biotechnologies vs Pfizer CentreOne
How does FUJIFILM Diosynth Biotechnologies compare to Pfizer CentreOne?
On CDMO Signal's composite Signal Score, FUJIFILM Diosynth Biotechnologies is 87/100 and Pfizer CentreOne is 90/100; FUJIFILM Diosynth Biotechnologies has 0 FDA inspections on record vs 4 for Pfizer CentreOne; European coverage is 35 active EMA+MHRA certificates for FUJIFILM Diosynth Biotechnologies vs 14 for Pfizer CentreOne. Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, FUJIFILM Diosynth Biotechnologies or Pfizer CentreOne?
Both FUJIFILM Diosynth Biotechnologies and Pfizer CentreOne maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. FUJIFILM Diosynth Biotechnologies has 0 FDA inspections on record; Pfizer CentreOne has 4.
How do FUJIFILM Diosynth Biotechnologies and Pfizer CentreOne compare on European GMP coverage?
FUJIFILM Diosynth Biotechnologies holds 29 active EMA GMP certificates and 6 MHRA / UK certificates. Pfizer CentreOne holds 14 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — FUJIFILM Diosynth Biotechnologies or Pfizer CentreOne?
FUJIFILM Diosynth Biotechnologies is matched to 0 ClinicalTrials.gov records as a manufacturing partner; Pfizer CentreOne is matched to 369. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
What does the Signal Score gap mean in practice?
FUJIFILM Diosynth Biotechnologies carries a Signal Score of 87/100 and Pfizer CentreOne carries 90/100 — essentially tied for Pfizer CentreOne. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →